- Home
- LRE vs EVAX Comparison
LRE vs EVAX Comparison
Compare LRE & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LRE
- EVAX
- Stock Information
- Founded
- LRE 2001
- EVAX 2008
- Country
- LRE Japan
- EVAX Denmark
- Employees
- LRE N/A
- EVAX N/A
- Industry
- LRE
- EVAX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LRE
- EVAX Health Care
- Exchange
- LRE Nasdaq
- EVAX Nasdaq
- Market Cap
- LRE 20.5M
- EVAX 17.8M
- IPO Year
- LRE 2023
- EVAX 2021
- Fundamental
- Price
- LRE $2.22
- EVAX $2.93
- Analyst Decision
- LRE
- EVAX Strong Buy
- Analyst Count
- LRE 0
- EVAX 2
- Target Price
- LRE N/A
- EVAX $10.00
- AVG Volume (30 Days)
- LRE 2.2M
- EVAX 68.5K
- Earning Date
- LRE 07-30-2015
- EVAX 10-30-2025
- Dividend Yield
- LRE N/A
- EVAX N/A
- EPS Growth
- LRE N/A
- EVAX N/A
- EPS
- LRE N/A
- EVAX N/A
- Revenue
- LRE $110,330,328.00
- EVAX $3,176,000.00
- Revenue This Year
- LRE N/A
- EVAX N/A
- Revenue Next Year
- LRE N/A
- EVAX $425.50
- P/E Ratio
- LRE N/A
- EVAX N/A
- Revenue Growth
- LRE 3.92
- EVAX 1042.45
- 52 Week Low
- LRE $1.00
- EVAX $1.20
- 52 Week High
- LRE $2.97
- EVAX $16.69
- Technical
- Relative Strength Index (RSI)
- LRE 73.39
- EVAX 51.89
- Support Level
- LRE $1.29
- EVAX $2.81
- Resistance Level
- LRE $2.97
- EVAX $3.04
- Average True Range (ATR)
- LRE 0.26
- EVAX 0.21
- MACD
- LRE 0.10
- EVAX -0.00
- Stochastic Oscillator
- LRE 61.93
- EVAX 68.64
About LRE Lead Real Estate Co. Ltd
Lead Real Estate Co Ltd operates as a developer of luxury residential properties, including single-family homes and condominiums, across Tokyo, Kanagawa prefecture, and Sapporo. The company also operates hotels in Tokyo and leases apartment building units to individual customers in Japan and Dallas, Texas. Predominantly, its revenue is generated from developing and selling single-family homes and condominiums. The company's sole operating segment is real estate sales. Geographically, it derives revenue from Japan.
About EVAX Evaxion Biotech
Evaxion AS is a techBio company based on its AI platform, AI-Immunology. Evaxion's proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing innovative and targeted treatment options.